EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

[1]  N. St-Pierre,et al.  Effects of transient changes in silage dry matter concentration on lactating dairy cows. , 2013, Journal of dairy science.

[2]  C. Rock,et al.  Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252 , 2013, Antimicrobial Agents and Chemotherapy.

[3]  Steven J. M. Jones,et al.  Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.

[4]  K. Aldape,et al.  Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. , 2012, Neuro-oncology.

[5]  R. McLendon,et al.  Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. , 2011, Cancer cell.

[6]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[8]  P. Birner,et al.  STAT3 tyrosine phosphorylation influences survival in glioblastoma , 2010, Journal of Neuro-Oncology.

[9]  F. Ali-Osman,et al.  Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes , 2010, Molecular Cancer Research.

[10]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  John Kuriyan,et al.  Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.

[12]  David S. Yang,et al.  The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas , 2008, Clinical Cancer Research.

[13]  G. Carpenter,et al.  Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation , 2007, Proceedings of the National Academy of Sciences.

[14]  K. Shokat,et al.  A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. , 2007, Cancer research.

[15]  Chao Zhang,et al.  Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. , 2007, Nature chemical biology.

[16]  A. Scott,et al.  The Efficacy of Epidermal Growth Factor Receptor–Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization , 2007, Clinical Cancer Research.

[17]  R. McLendon,et al.  Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma , 2006, Clinical Cancer Research.

[18]  Kimmo J Hatanpaa,et al.  Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.

[19]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[20]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[21]  W. Weiss,et al.  RNA interference against a glioma-derived allele of EGFR induces blockade at G2M , 2005, Oncogene.

[22]  A. Scott,et al.  The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR , 2004, Oncogene.

[23]  P. Kleihues,et al.  Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas , 2004, Brain pathology.

[24]  K. Aldape,et al.  Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR , 2004, Genes, chromosomes & cancer.

[25]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[26]  Huang Shao,et al.  Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.

[27]  Peter G. Schultz,et al.  A chemical switch for inhibitor-sensitive alleles of any protein kinase , 2000, Nature.

[28]  A. Bishayee,et al.  Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail. , 1999, Molecular biology of the cell.

[29]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[30]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[31]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  W. Cavenee,et al.  Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma , 2006, Brain Tumor Pathology.